Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

161. Dietary sodium intake as a risk factor for osteoporosis: a systematic review

Dietary sodium intake as a risk factor for osteoporosis: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect

2017 PROSPERO

162. The prevalence, diagnosis, and risk factors of osteoporosis in individuals with chronic obstructive pulmonary disease (COPD) - a systematic review and meta-analysis

The prevalence, diagnosis, and risk factors of osteoporosis in individuals with chronic obstructive pulmonary disease (COPD) - a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g

2017 PROSPERO

163. Association between sarcoidosis and osteoporosis: a systematic review and meta-analysis

Association between sarcoidosis and osteoporosis: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2017 PROSPERO

164. Relative effectiveness of osteoporosis medications on preventing fractures in men and women: a systematic review and network meta-analysis

Relative effectiveness of osteoporosis medications on preventing fractures in men and women: a systematic review and network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2017 PROSPERO

165. The anti fracture efficacy of different anti osteoporosis medications in the male population: a systematic review and meta-analysis

The anti fracture efficacy of different anti osteoporosis medications in the male population: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2017 PROSPERO

166. Exercise to improve functional outcomes in persons with osteoporosis

Exercise to improve functional outcomes in persons with osteoporosis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures

2017 PROSPERO

167. Association between consumption of soft drinks and osteoporosis: protocol for a systematic review of observational studies

Association between consumption of soft drinks and osteoporosis: protocol for a systematic review of observational studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2017 PROSPERO

168. Denosumab for the treatment of postmenopausal women with osteoporosis at high risk of fracture

Denosumab for the treatment of postmenopausal women with osteoporosis at high risk of fracture '); } else { document.write(' '); } ACE | Denosumab for the treatment of postmenopausal women with osteoporosis at high risk of fracture Search > > Denosumab for the treatment of postmenopausal women with osteoporosis at high risk of fracture - Denosumab for the treatment of postmenopausal women with osteoporosis at high risk of fracture Published on 3 May 2017 Guidance Recommendations The Ministry (...) of Health’s Drug Advisory Committee has recommended: Denosumab 60 mg pre-filled syringe for the treatment of osteoporosis (T-score ≤ -2.5) in post-menopausal women at high risk of fracture, who: have a renal function eGFR > 30 ml/min, and are unable to tolerate or follow the administration instructions for oral bisphosphonates. Patients must also receive adequate calcium and vitamin D supplementation whilst undergoing treatment. Subsidy status Denosumab 60 mg pre-filled syringe is recommended

2017 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

169. An overview and management of osteoporosis Full Text available with Trip Pro

An overview and management of osteoporosis Osteoporosis -related to various factors including menopause and aging- is the most common chronic metabolic bone disease, which is characterized by increased bone fragility. Although it is seen in all age groups, gender, and races, it is more common in Caucasians (white race), older people, and women. With an aging population and longer life span, osteoporosis is increasingly becoming a global epidemic. Currently, it has been estimated that more than (...) 200 million people are suffering from osteoporosis. According to recent statistics from the International Osteoporosis Foundation, worldwide, 1 in 3 women over the age of 50 years and 1 in 5 men will experience osteoporotic fractures in their lifetime. Every fracture is a sign of another impending one. Osteoporosis has no clinical manifestations until there is a fracture. Fractures cause important morbidity; in men, in particular, they can cause mortality. Moreover, osteoporosis results

2016 European journal of rheumatology

170. Cost-Effectiveness of Zoledronic Acid to Prevent and Treat Postmenopausal Osteoporosis in Comparison with Routine Medical Treatment Full Text available with Trip Pro

Cost-Effectiveness of Zoledronic Acid to Prevent and Treat Postmenopausal Osteoporosis in Comparison with Routine Medical Treatment Fractures caused by osteoporosis are prevalent among elderly females, which reduce quality of life significantly. This study aimed at comparing cost-effectiveness of Zoledronic acid in preventing and treating post-menopause osteoporosis as compared with routine medical treatment.This cost-effectiveness study was carried out retrospectively from the Ministry (...) fracture for a 36-month period were about 0.82, 0.57, and 1.06, respectively. Vertebral and hip fractures, and non-vertebral fractures or any clinical fracture for a 12-month period were calculated as 1.14 and 0.64, respectively. In other words, Zoledronic acid consumption approach is a cheaper and better approach based on an economic assessment, and it can be considered as a dominant approach.According to the cost-effectiveness of zoledronic acid in the prevention and treatment of osteoporosis

2016 Electronic physician

171. Denosumab versus Zoledronic Acid for Adults with Osteoporosis: A Review of Cost-Effectiveness

Denosumab versus Zoledronic Acid for Adults with Osteoporosis: A Review of Cost-Effectiveness Denosumab versus Zoledronic Acid for Adults with Osteoporosis: A Review of Cost-Effectiveness | CADTH.ca Find the information you need Denosumab versus Zoledronic Acid for Adults with Osteoporosis: A Review of Cost-Effectiveness Denosumab versus Zoledronic Acid for Adults with Osteoporosis: A Review of Cost-Effectiveness Published on: December 12, 2016 Project Number: RC0829-000 Product Line: Research (...) Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the cost-effectiveness of denosumab versus zoledronic acid in patients with osteoporosis? Key Message Two studies were identified that evaluated the cost-effectiveness of denosumab for the treatment of elderly men with osteoporosis, from a payer perspective in the United States or Sweden. Both studies found that subcutaneous denosumab 60 mg administered once every six months was associated with lower-costs

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

172. Denosumab versus Zoledronic Acid for Men with Osteoporosis: Clinical Effectiveness and Guidelines

Denosumab versus Zoledronic Acid for Men with Osteoporosis: Clinical Effectiveness and Guidelines Denosumab versus Zoledronic Acid for Men with Osteoporosis: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Denosumab versus Zoledronic Acid for Men with Osteoporosis: Clinical Effectiveness and Guidelines Denosumab versus Zoledronic Acid for Men with Osteoporosis: Clinical Effectiveness and Guidelines Published on: November 28, 2016 Project Number: RC0828-000 Product (...) Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical effectiveness of denosumab versus zoledronic acid in male patients with osteoporosis? What is the comparative clinical effectiveness of denosumab versus zoledronic acid in male patients with osteoporosis and non-metastatic prostate cancer receiving adjuvant anti-androgen therapy? What are the evidence-based guidelines regarding the use of denosumab and zoledronic acid

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

173. Lifestyle-Related Metabolic Disorders, Osteoporosis, and Fracture Risk in Asia: A Systematic Review. Full Text available with Trip Pro

Lifestyle-Related Metabolic Disorders, Osteoporosis, and Fracture Risk in Asia: A Systematic Review. The prevalence of both lifestyle-related metabolic disorders and osteoporosis is increasing in Asia.To conduct a systematic review of the published literature to identify studies examining disorders of glucose and lipid metabolism (type 2 diabetes, hyperglycemia, hypercholesterolemia, hyperlipidemia, dyslipidemia, metabolic syndrome [MetS], and atherosclerosis) as risk factors for osteoporosis (...) than did subjects without diabetes (risk estimate range 1.26-4.73). Two studies found that subjects with atherosclerosis had a significantly higher risk of fracture (risk estimate range 1.10-2.52). Studies consistently reported that MetS is likely associated with osteoporosis or decreased BMD in men but not women. No consistent association was found for diabetes and BMD, with studies reporting contrasting results. There was limited evidence investigating lipid metabolism and hyperglycemia and risk

2016 Value in health regional issues

174. The Occurrence of Subclinical Hypercortisolism and Osteoporosis in Patients with Incidentally Discovered Unilateral and Bilateral Adrenal Tumors Full Text available with Trip Pro

The Occurrence of Subclinical Hypercortisolism and Osteoporosis in Patients with Incidentally Discovered Unilateral and Bilateral Adrenal Tumors Adrenal incidentalomas (AI) are clinically silent adrenal masses that are detected incidentally during imaging procedures performed for unrelated diseases. The aim of this study was to investigate the prevalence of sub-clinical hypercortisolism (SH) and associated co-morbidities in patients with unilateral AI (UAI) and bilateral AI (BAI).We evaluated (...) , and diabetes, hypertension and dyslipidemia occurred with similar frequency in both groups. The overall prevalence of SH was 20.5% based on post-1 mg DST, and 20.0% based on post-LDDST cortisol levels, and it was more prevalent in BAI than UAI patients (31.1% vs 15.2%, respectively, p=0.026). LS BMD was lower in BAI than in UAI patients (0.96±0.14 vs 0.87±0.15, p=0.002). There were no differences in FN BMD. The prevalence of osteoporosis was higher in BAI compared to UAI patients (37.1% vs 15.9

2016 Journal of medical biochemistry

175. Lack of Evidence Linking Calcium With or Without Vitamin D Supplementation to Cardiovascular Disease in Generally Healthy Adults: A Clinical Guideline From the National Osteoporosis Foundation and the American Society for Preventive Cardiology. Full Text available with Trip Pro

Lack of Evidence Linking Calcium With or Without Vitamin D Supplementation to Cardiovascular Disease in Generally Healthy Adults: A Clinical Guideline From the National Osteoporosis Foundation and the American Society for Preventive Cardiology. Calcium is the dominant mineral present in bone and a shortfall nutrient in the American diet. Supplements have been recommended for persons who do not consume adequate calcium from their diet as a standard strategy for the prevention of osteoporosis (...) and related fractures. Whether calcium with or without vitamin D supplementation is beneficial or detrimental to vascular health is not known.The National Osteoporosis Foundation and American Society for Preventive Cardiology convened an expert panel to evaluate the effects of dietary and supplemental calcium on cardiovascular disease based on the existing peer-reviewed scientific literature. The panel considered the findings of the accompanying updated evidence report provided by an independent evidence

2016 Annals of Internal Medicine

176. Love your bones: finding and treating osteoporosis

Love your bones: finding and treating osteoporosis Love your bones: finding and treating osteoporosis - Evidently Cochrane Search and hit Go By October 20, 2016 // Today is World Osteoporosis Day. We’re taking a look at the campaign and at Cochrane evidence on osteoporosis. Be proactive and #LoveYourBones is the message of this year’s . The campaign is a call to action for members of the public to act early to protect their bone and muscle health, and for health professionals and those who fund (...) health care to prioritize osteoporosis and fracture prevention by ensuring that people who are at high risk are assessed and offered appropriate treatment. People are also being asked to raise awareness of the campaign by wearing white, not a colour that does anything for me, so instead I’m blogging some Cochrane evidence. What is osteoporosis? Osteoporosis is a condition that weakens bones through a reduction in bone mineral density (BMD), making the risk of broken bones (fractures) more likely

2016 Evidently Cochrane

177. Comparative Efficacy of Bisphosphonates to Prevent Fracture in Men with Osteoporosis: A Systematic Review with Network Meta-Analyses. Full Text available with Trip Pro

Comparative Efficacy of Bisphosphonates to Prevent Fracture in Men with Osteoporosis: A Systematic Review with Network Meta-Analyses. Osteoporosis is an under-recognized problem threatening men. Bisphosphonates are the main treatment but their comparative efficacy is unclear for men with osteoporosis. Therefore, we performed this systematic review with network meta-analyses to summarize the evidence of comparative efficacy of bisphosphonates in men with osteoporosis.We completed network meta (...) -analyses with a frequentist model to compare the efficacy of different bisphosphonates. Randomized controlled trials investigating bisphosphonates used in men with osteoporosis were included. The primary outcome was the rate of patients with a new vertebral fracture. The secondary outcome was the rate of patients with a non-vertebral fracture, which was defined as any fractures reported other than vertebral fractures. Pairwise meta-analyses were performed to compare bisphosphonates with placebo. We

2016 Rheumatology and therapy

178. Prevalence of Osteoporosis and Its Risk Factors in Men with COPD in Qazvin Full Text available with Trip Pro

Prevalence of Osteoporosis and Its Risk Factors in Men with COPD in Qazvin Introduction. Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide. Proper diagnosis of osteoporosis as a systemic adverse effect of COPD is of significant importance. The present study aimed at evaluating the prevalence of osteoporosis and its risk factors in men suffering from COPD in Qazvin (2014). Methods. This descriptive-analytical study was conducted on 90 patients (...) with COPD using random sampling. Anthropometric data and results from physical examination were collected. Pulmonary function test and bone mineral densitometry were done for all participants as well. Results. The prevalence of osteopenia and osteoporosis in COPD patients was 31.5 and 52.8 percent, respectively. Bone mineral density (BMD) at the femoral neck was associated significantly with body mass index (BMI), increased severity of COPD, and use of oral corticosteroid (P < 0.05). Conclusion

2016 International journal of chronic diseases

179. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. Full Text available with Trip Pro

Romosozumab Treatment in Postmenopausal Women with Osteoporosis. Romosozumab, a monoclonal antibody that binds sclerostin, increases bone formation and decreases bone resorption.We enrolled 7180 postmenopausal women who had a T score of -2.5 to -3.5 at the total hip or femoral neck. Patients were randomly assigned to receive subcutaneous injections of romosozumab (at a dose of 210 mg) or placebo monthly for 12 months; thereafter, patients in each group received denosumab for 12 months (...) the transition to denosumab (0.6% [21 of 3325 patients] in the romosozumab group vs. 2.5% [84 of 3327] in the placebo group, a 75% lower risk with romosozumab; P<0.001). Adverse events, including instances of hyperostosis, cardiovascular events, osteoarthritis, and cancer, appeared to be balanced between the groups. One atypical femoral fracture and two cases of osteonecrosis of the jaw were observed in the romosozumab group.In postmenopausal women with osteoporosis, romosozumab was associated with a lower

2016 NEJM Controlled trial quality: uncertain

180. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. Additional therapies are needed for prevention of osteoporotic fractures. Abaloparatide is a selective activator of the parathyroid hormone type 1 receptor.To determine the efficacy and safety of abaloparatide, 80 μg, vs placebo for prevention of new vertebral fracture in postmenopausal women at risk of osteoporotic fracture.The Abaloparatide Comparator Trial (...) greater with abaloparatide than placebo (all P < .001). Incidence of hypercalcemia was lower with abaloparatide (3.4%) vs teriparatide (6.4%) (risk difference [RD], −2.96 [95%CI, −5.12 to −0.87]; P = .006). [table: see text].Among postmenopausal women with osteoporosis, the use of subcutaneous abaloparatide, compared with placebo, reduced the risk of new vertebral and nonvertebral fractures over 18 months. Further research is needed to understand the clinical importance of RD, the risks and benefits

2016 JAMA Controlled trial quality: predicted high